GLP-1 Drugs Linked to Reduced Substance Use Disorders in US Veterans
Large veteran cohort study finds GLP-1 receptor agonists associated with reduced risk of new substance use disorders and better outcomes in those with existing addictions.
Quick Facts
What This Study Found
GLP-1 RA initiation was associated with reduced incidence of alcohol, cannabis, cocaine, nicotine, opioid, and other SUDs in veterans without prior addictions, and reduced adverse outcomes in those with pre-existing SUDs.
Key Numbers
How They Did This
Target trial emulation using veteran cohort data with two protocols: (1) incident SUD risk in SUD-free veterans, (2) clinical outcomes in veterans with pre-existing SUDs, comparing GLP-1 RA initiators to non-users.
Why This Research Matters
Substance use disorders affect millions and have limited treatments. If GLP-1 drugs reduce addiction risk, they could benefit an enormous population beyond diabetes patients.
The Bigger Picture
This adds to growing evidence that GLP-1 receptor signaling modulates reward pathways, positioning these drugs as potential treatments for addiction — a paradigm-shifting possibility.
What This Study Doesn't Tell Us
Observational study — cannot prove causation. Veterans may not represent the general population. Healthy user bias possible.
Questions This Raises
- ?Should GLP-1 drugs be tested in dedicated addiction treatment trials?
- ?Does the anti-addiction effect persist after GLP-1 drug discontinuation?
Trust & Context
- Key Stat:
- 6 substance categories, 2 protocols GLP-1 RAs associated with reduced addiction risk and improved SUD outcomes in veterans
- Evidence Grade:
- Large observational cohort with target trial emulation — strong methodology for observational evidence, but causation not established.
- Study Age:
- Published in 2026; among the most comprehensive studies of GLP-1 drugs and addiction.
- Original Title:
- Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.
- Published In:
- BMJ (Clinical research ed.), 392, e086886 (2026)
- Authors:
- Cai, Miao, Choi, Taeyoung, Xie, Yan(2), Al-Aly, Ziyad
- Database ID:
- RPEP-14921
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs help with addiction?
This large study of US veterans found that people who started GLP-1 drugs had lower rates of developing substance use disorders and better outcomes if they already had addictions. Clinical trials are needed to confirm this potential benefit.
How might weight loss drugs reduce addiction?
GLP-1 receptors are found in brain reward centers that drive both food cravings and substance addiction. By modulating these pathways, GLP-1 drugs may reduce the neurological drive behind addictive behaviors.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14921APA
Cai, Miao; Choi, Taeyoung; Xie, Yan; Al-Aly, Ziyad. (2026). Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.. BMJ (Clinical research ed.), 392, e086886. https://doi.org/10.1136/bmj-2025-086886
MLA
Cai, Miao, et al. "Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.." BMJ (Clinical research ed.), 2026. https://doi.org/10.1136/bmj-2025-086886
RethinkPeptides
RethinkPeptides Research Database. "Glucagon-like peptide-1 receptor agonists and risk of substa..." RPEP-14921. Retrieved from https://rethinkpeptides.com/research/cai-2026-glucagonlike-peptide1-receptor-agonists
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.